logo

Bridgebio Pharma, Inc. (BBIO)



Trade BBIO now with
  Date
  Headline
3/20/2021 11:42:15 AM BridgeBio Pharma Announces Proof-of-Concept Data Of Encaleret In ADH1 At Endocrine Society’s 2021 Annual Meeting
2/19/2021 7:33:45 AM BridgeBio And ML Bio Solutions Dose First Patient In Phase 2 Trial Of BBP-418 In Limb Girdle Muscular Dystrophy Type 2i
1/26/2021 12:08:03 AM BridgeBio Pharma Prices $650 Mln Of 2.25% Convertible Notes Due 2029 In A Private Offering To Institutional Buyers
1/25/2021 7:12:24 AM BridgeBio Pharma Announces Proposed Offering Of $400 Mln Of Convertible Senior Notes Due 2029
1/25/2021 7:09:47 AM BridgeBio Pharma Announces Proposed Offering Of $400 Mln Convertible Senior Notes
1/4/2021 7:46:05 AM ISS Recommends BridgeBio Pharma, Eidos Therapeutics Stockholders Vote For Proposed Merger
12/23/2020 7:37:58 AM UCSF And BridgeBio Pharma Collaborate To Accelerate Development Of Therapies For Genetic Diseases
10/5/2020 7:09:55 AM BridgeBio Agrees To Acquire All Outstanding Shares Of Eidos It Does Not Already Own
9/29/2020 7:37:19 AM BridgeBio Pharma: FDA Accepts NDA For Fosdenopterin For The Treatment Of MoCD Type A
7/15/2020 7:39:20 AM BridgeBio Pharma’s QED Therapeutics Doses First Child In Phase 2 Clinical Trial Of Infigratinib In Achondroplasia
6/11/2020 7:10:03 AM ML Bio Solutions Says First Subject Has Been Dosed In Phase 1 Trial Of BBP-418 For LGMD2i
3/4/2020 7:08:55 AM BridgeBio Pharma Plans Proposed Offering Of $350 Mln Convertible Senior Notes
2/24/2020 7:35:01 AM BridgeBio Pharma Appoints Ronald Daniels To Its Board
1/13/2020 7:41:46 AM BridgeBio Pharma Discloses Four Additional Assets In Its Pipeline
1/8/2020 8:12:54 AM PellePharm Begins Phase 2 Clinical Trial Of Patidegib Topical Gel For People With High Frequency Basal Cell Carcinoma